

IN THE CLAIMS:

A clean version of the entire set of pending claims is set forth below, for clarity. A version of the amended claims with markings to show changes made relative to the previous versions of such amended claims is attached hereto as **Appendix A**.

1. A method of determining whether a treatment is effective in changing a status of a certain set of target cells in an individual comprising:
obtaining a sample from said individual after initiating said treatment; and
determining whether said sample comprises an expression product of at least one marker gene.
2. The method according to claim 1, wherein said target cells comprise a tumor cell.
3. (Previously Amended) The method according to claim 1, wherein said sample comprises at least one of said target cells.
4. (Previously Amended) The method according to claim 1, wherein said sample is obtained within one week of initiating said treatment.
5. (Previously Amended) The method according to claim 1, wherein said sample is obtained within two days of initiating said treatment.
6. (Twice Amended) The method according to claim 1, wherein said at least one marker gene comprises a gene involved in the generation, maintenance and/or breakdown of blood vessels.
7. (Twice Amended) The method according to claim 1, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31.

8. (Twice Amended) The method according to claim 1, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:65-82 or a part or analogue thereof.

9. (Twice Amended) The method according to claim 1, wherein expression of said at least one marker gene is quantified.

10. (Twice Amended) The method according to claim 1, further comprising comparing expression of said at least one marker gene with a reference value.

11. (Twice Amended) The method according to claim 2, wherein said tumor cell comprises Kaposi's Sarcoma.

12. (Amended) A method of detecting an expression product of a marker gene comprising:
obtaining a sample from an individual;
introducing a nucleic acid to said sample, said nucleic acid selected from the group consisting of
SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof; and
determining whether said nucleic acid hybridizes in said sample.

13. (Amended) A method of detecting an expression product of a marker gene comprising:
incubating a proteinaceous molecule to a sample from an individual, said proteinaceous molecule
capable of specifically binding a protein encoded by a nucleic acid selected from the group
consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof; and
detecting binding between said proteinaceous molecule and said protein.

14. (Twice Amended) The method according to claim 12, further comprising determining the presence of a tumor cell in said individual.

15. (Twice Amended) The method according to claim 12, further comprising determining the presence of a site of angiogenesis in said individual.

16. (Twice Amended) The method according to claim 12, further comprising determining whether a treatment is effective in changing the status of a certain set of target cells in said individual.

17. (Previously Amended) The method according to claim 12, further comprising determining whether a treatment is effective in counteracting a tumor in said individual.

18. (Twice Amended) The method according to claim 14, wherein said tumor cell comprises Kaposi's Sarcoma.

19. A method for determining whether an individual possesses a tumor cell and/or a site of angiogenesis, comprising:
obtaining a sample from said individual; and
determining whether said sample comprises an expression product of at least one marker gene.

20. (Amended) The method according to claim 19, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

21. A method of determining whether an individual possesses a non-hemopoietic tumor cell and/or a site of angiogenesis, said method comprising determining whether a hemopoietic cell from said individual comprises an altered amount of an expression product of a marker gene as compared with a reference value.

22. The method according to claim 21, wherein said marker gene comprises a gene involved in angiogenesis.

23. (Twice Amended) The method according to claim 21, wherein said marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

24. (Previously Amended) The method according to claim 21, wherein said hemopoietic cell comprises a peripheral blood mononuclear cell.

25. A method of determining whether a treatment is effective in altering an angiogenic process in an individual comprising:
obtaining a first sample from said individual before initiating said treatment;
obtaining a second sample from said individual after initiating said treatment; and
comparing expression of an expression product of at least one marker gene in said first sample and said second sample.

26. The method according to claim 25, wherein said treatment comprises counteracting angiogenesis in said individual.

27. (Twice Amended) The method according to claim 25, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

28. (Previously Amended) The method according to claim 25, wherein said treatment involves the use of at least one drug selected from the group consisting of 2ME2, Angiostatin, Angiozyme, Anti-VEGF RhuMAb, Apra (CT-2584), Avicine, Benefin, BMS275291, Carboxyamidotriazole, CC44047, CC5013, CC7085, CDC801, CGP-41251 (PKC 412), CM101, Combretastatin A-4 Prodrug, EMD 121974, Endostatin, Flavopiridol, Genistein (GCP), Green Tea Extract, IM-862, ImmTher, Interferon alpha, Interleukin-12, Iressa (ZD1839), Marimastat, Metastat (Col-3), Neovastat, Octreotide, Paclitaxel, Penicillamine, Photofrin, Photopoint, PI-88, Prinomastat (AG-3340), PTK787 (ZK22584), RO317453, Solimastat, Squalamine, SU 101, SU 5416, SU-6668, Suradista (FCE 26644), Suramin (Metaret), Tetrathiomolybdate, Thalidomide, TNP-470, and Vitaxin.

29. (Previously Amended) The method according to claim 1, wherein said sample is a blood sample.

30. (Previously Amended) The method according to claim 1, wherein said sample comprises a peripheral blood mononuclear cell.

31. (Twice Amended) The method according to claim 1, wherein said expression product comprises one of SEQ ID NOS:6, 30, 72 and 81, or a part or analogue thereof.

32. (Amended) A method of detecting angiogenesis comprising detecting peripheral blood mononuclear cell expression of at least one of SEQ ID NOS:6, 18, 30, 66, 72 and 81, or a part or analogue thereof.

33. (Amended) A method of determining the presence of a tumor cell in an individual comprising:
obtaining a sample from said individual; and
detecting the level of peripheral blood mononuclear cell expression of at least one of SEQ ID NOS:6, 18, 30, 66, 72 and 81, or a part or analogue thereof.

34. (Amended) A method of diagnosing presence of disease comprising comparing expression of an isolated sequence of SEQ ID NOS:6, 18, 30, 66, 72 and 81, or a part or analogue thereof, in an individual to a reference value.

35. (Amended) A diagnostic kit comprising a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof, and a proteinaceous molecule capable of specifically binding a protein encoded by said nucleic acid or said part or analogue thereof.

36. (Amended) The diagnostic kit according to claim 35, further comprising at least one of SEQ ID NOS:6, 18, 30, 66, 72, and 81, or a part or analogue thereof.

37. (Previously Amended) A method of determining whether a treatment is effective in changing the status of a certain set of target cells in an individual and/or altering an angiogenic process in an individual, said method comprising:
providing the diagnostic kit according to claim 35;
obtaining a sample from said individual; and
detecting the presence of an expression product of at least one marker gene in said sample.

38. (Previously Amended) A method of determining whether an individual possesses a tumor cell and/or a site of angiogenesis, said method comprising:
providing the diagnostic kit according to claim 35;
obtaining a sample from said individual; and
quantifying an expression product of at least one marker gene in said sample.

39. (Amended) A method for identifying desired drug activity comprising:
determining an expression pattern of a marker gene in cells;
incubating said cells with an expression product of a gene comprising one of SEQ ID NOS:1-31 and 65-82; and
detecting an alteration in said expression pattern of said marker gene after said incubating.

40. (Amended) A compound capable of altering the activity of at least one of SEQ ID NOS:66, 72, and 81, and the expression of at least one of SEQ ID NOS:66, 72, and 81 in a cell.

41. (Amended) A method of preparing a medicament comprising:
identifying a compound capable of altering the activity of at least one of SEQ ID NOS:66, 72, and 81, and the expression of at least one of SEQ ID NOS:66, 72, and 81 in a cell; and
incorporating said identified compound into a medicament.